Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
TACE is an oral capsule small-molecule NDA product sponsored by Sanofi currently in pre-launch stage. The mechanism of action, indication(s), and pharmacologic class are undisclosed in available data. Patient population cannot be determined without indication clarity.
Early-stage pre-launch product with undefined commercial trajectory; team size and staffing expansion unknown pending approval and market definition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
TACE Treats Nodular Goiter
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Worked on TACE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TACE offers pre-launch career opportunity with Sanofi, a major pharmaceutical employer, though current job availability is minimal. Career trajectory depends heavily on regulatory approval timing and competitive market dynamics post-launch.